外体miR-155-5p驱动B细胞淋巴瘤中的易布鲁替尼抗性
Bon Park1, Myung Eun Choi1, Kyung Ju Ryu1
1Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, South Korea.
Experimental cell research
|September 11, 2024
概括
在B细胞淋巴瘤中获得的耐药性与IBR-155-5p的增加有关. 这种微RNA通过激活AKT/NF-κB通路来促进耐药性,并且可以通过外体转移.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 易布鲁替尼对B细胞恶性瘤有效,但获得的耐药性限制了其长期疗效.
- 微RNA-155-5p (miR-155-5p) 与B细胞淋巴瘤的预后不佳有关.
- 了解耐药机制对于改善治疗结果至关重要.
研究的目的:
- 调查miR-155-5p在B细胞淋巴瘤中获得的IBRUTINIB耐药性的作用.
- 阐明基底的分子机制miR-155-5p介导的易布鲁丁尼布耐药性.
- 探索针对miR-155-5p或其通路的潜力.
主要方法:
- 通过连续药物暴露产生抗易布鲁替尼布的OCI-Ly1细胞 (OCI-Ly1-IbtR).
- 通过超离心分离分离的细胞和外体的微RNA分析.
- 转染研究以验证microRNA目标和功能影响.
- 共同培养实验以评估外体介导的细胞间通信.
主要成果:
- 在ibrutinib耐药细胞及其外体中发现了高的miR-155-5p水平,与AKT和NF-κB激活相关.
- miR-155-5p传染引发了易布鲁替尼抗性,增强了细胞增殖,并持续了布鲁顿氨酸激酶 (BTK) 活性.
- 鉴定出KDM5B和DEPTOR是miR-155-5p的直接标,在传染后证实了它们的下调.
- 来自耐药细胞的外体细胞将miR-155-5p转移到敏感细胞,赋予耐药性和降低目标.
结论:
- 获得的miR-155-5p的过度表达有助于B细胞淋巴瘤中的易布鲁替尼抗性.
- miR-155-5p通过激活AKT/NF-κB信号通路来促进抵抗.
- 通过外体介导的miR-155-5p的转移代表了一种新的抵抗传播机制.
更多相关视频
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
15.3K
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
6.1K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
01:06Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K